金融投资网记者张璐璇 近期，A股医药板块表现亮眼。上周，A股生物医药指数上涨6.27%，显著超越同期沪深300指数涨幅；本周以来，创新药、CXO概念股继续冲高。多家机构认为，进入8月中报披露期，创新药商业化进展成为市场核心主线之一。“2026年中报季有望成为验证商业化逻辑、重塑板块估值的重要窗口。龙头股打头阵已定调，行业整体表现值得期待。”东吴证券研究所指出。 据Wind数据统计，截至8月10...
Source Link金融投资网记者张璐璇 近期，A股医药板块表现亮眼。上周，A股生物医药指数上涨6.27%，显著超越同期沪深300指数涨幅；本周以来，创新药、CXO概念股继续冲高。多家机构认为，进入8月中报披露期，创新药商业化进展成为市场核心主线之一。“2026年中报季有望成为验证商业化逻辑、重塑板块估值的重要窗口。龙头股打头阵已定调，行业整体表现值得期待。”东吴证券研究所指出。 据Wind数据统计，截至8月10...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.